phase II trial interferon gamma monoclon antibodi pancreat cancer biolog clinic effect thirti patient advanc measur pancreat adenocarcinoma phase II trial recombin interferon gamma biogen cambridg MA day monoclon antibodi mab centocor malvern PA mg autolog leukocyt day interferon infus effect singl interferon gamma treatment natur antibody-depend cellular cytotox adcc Fc receptor occup antibodi human leukocyt antigen-dr hla-dr express monocyt lymphocyt toxic modest II fever nausea vomit hepatotox patient nonassess respons assess patient object respons complet remiss durat month stabl diseas month patient median surviv group month analysi cytotox data treatment reduc natur cytotox activ patient normal volunt signific improv natur cytotox activ normal level hour interferon gamma infus augment antibody-depend cellular cytotox hla-dr express monocyt lymphocyt capac lymphocyt monocyt mab vitro assay adcc presenc antibodi excess improv cytolyt activ spite favor modul cytolyt activ improv abil effector cell mab adequ clinic efficaci treatment patient pancreat adenocarcinoma dose schedul interferon gamma mab futur trial altern schedul mab hope tumor antigen satur circul level infus antibodi 